FTEL vs NAUT

Analysts rate Nautilus Biotechnology, Inc.

(NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nautilus Biotechnology, Inc.

(NAUT) delivered a total return of -71. 3%, compared to -95. 3% for Fitell Corporation (FTEL). Over 10 years, the gap is even starker: NAUT returned -74. 3% versus FTEL's -95. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Fitell Corporation (FTEL) is the lower-risk stock at 1.

19β versus Nautilus Biotechnology, Inc. 's 1. 77β — meaning NAUT is approximately 49% more volatile than FTEL relative to the S&P 500. On balance sheet safety, Fitell Corporation (FTEL) carries a lower debt/equity ratio of 6% versus 19% for Nautilus Biotechnology, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Nautilus Biotechnology, Inc.

grew EPS 16. 1% year-over-year, compared to -228. 6% for Fitell Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nautilus Biotechnology, Inc.

(NAUT) is the more profitable company, earning 0. 0% net margin versus -208. 5% for Fitell Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NAUT leads at 0. 0% versus -179. 1% for FTEL. At the gross margin level — before operating expenses — FTEL leads at 35. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Fitell Corporation (FTEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

19)). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FTEL: -95. 3%, NAUT: -74. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (FTEL (Consumer Cyclical) and NAUT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.